Promoter hypermethylation of GSTP1, AR, and 14‐3‐3σ in serum of prostate cancer patients and its clinical relevance

Reibenwein, Jochen; Pils, Dietmar; Horak, Peter; Tomicek, Birgit; Goldner, Gregor; Worel, Nina; Elandt, Katarzyna; Krainer, Michael

doi:10.1002/pros.20533

Cited by 77 publications

(53 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with most previous observations in prostate tumor tissue and blood ( Jeronimo et al, 2004;Yegnasubramanian et al, 2004;Reibenwein et al, 2007;Sunami et al, 2009;Steiner et al, 2010), we found that elevated DNA methylation levels in prostate tumor tissues were related to worse clinicopathological outcomes. Specifically, GSTP1, p16 (CDKN4A), and APC methylation levels were significantly associated with higher Gleason score.…”

Section: Discussionsupporting

confidence: 92%

DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer

Delgado‐Cruzata

Hruby

González

et al. 2012

DNA and Cell Biology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer

Delgado‐Cruzata

Hruby

González

et al. 2012

DNA and Cell Biology

View full text Add to dashboard Cite

“…Our hypermethylation frequency of GSTP1 was somewhat higher than those reported by other groups [12][13][14][15]18]. These differences maybe explained by different detection methods and/or differences in the study cohort: Bastian et al used also a restriction endonuclease method and detected GSTP1 hypermethylation in 12% of serum samples from PCA patients in a screening cohort with US-Americans.…”

Section: Discussioncontrasting

confidence: 70%

CpG Island hypermethylation in cell‐free serum DNA identifies patients with localized prostate cancer

et al. 2007

View full text Add to dashboard Cite

BACKGROUND.One of the earliest and most common epigenetic events in prostate carcinogenesis is DNA CpG island (CGI) hypermethylation. Our aim was to analyze the diagnostic and prognostic possibilities of multigene methylation analysis in cell-free serum DNA of prostate cancer (PCA) patients. METHODS. We analyzed serum samples from 226 consecutive patients (168 PCA; 42 benign prostatic hyperplasia (BPH); 5 incidental PCA; 11 healthy individuals). Cell-free DNA was digested with methylation-sensitive restriction endonucleases (HpaII and HinP1I). Subsequently, CGI hypermethylation at GSTP1, PTGS2, Reprimo, and TIG1 was assessed using real-time PCR. RESULTS. CGI hypermethylation at GSTP1, TIG1, PTGS2, and Reprimo was more frequent in PCA (42.3%, 9.5%, 2.4%, and 1.2%, respectively) compared to BPH (7.7%, 0%, 0%, and 0%, respectively) and healthy individuals (all 0%) with a statistical significant difference of GSTP1 (P < 0.0001) and TIG1 (P ¼ 0.038). GSTP1 hypermethylation was also detected in four patients with incidental PCA. Hypermethylation in serum DNA at GSTP1 and hypermethylation at any gene site distinguished between PCA and BPH patients in a highly specific (92%) but less sensitive (42-47%) manner. Neither CGI hypermethylation at a single gene loci nor the combination of multiple gene sites was correlated to the pathological stage, grade or biochemical recurrence following radical prostatectomy. CONCLUSIONS. The detection of aberrant hypermethylation in cell-free serum DNA allows the highly specific diagnosis of PCA. A test based on GSTP1 hypermethylation in serum samples of patients with suspected PCA may help to identify men with increased risk of harboring PCA despite negative prostate biopsy.

show abstract

“…RARB2 and GSTP1methylation were also correlated with the AJCC stage [82]. GSTP1 hypermethylation was the strongest predictor of PSA recurrence following radical prostatectomy [83] and it was correlated with the Gleason score and the extent of metastasis in patients with hormone-refractory PCA [84].…”

Section: Prostate Cancermentioning

confidence: 89%

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Espósito¹,

Bardelli²,

Criscitiello³

et al. 2014

Cancer Treatment Reviews

104

View full text Add to dashboard Cite

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression through 'liquid biopsies'. The serial monitoring of tumor genotypes, which are instable and prone to changes under selection pressure, is becoming increasingly possible. The "liquid biopsy" provide novel biological insights into the process of metastasis and may elucidate signaling pathways involved in cell invasiveness and metastatic competence. This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including genetic and epigenetic alterations that can be detected.

show abstract

Promoter hypermethylation of GSTP1, AR, and 14‐3‐3σ in serum of prostate cancer patients and its clinical relevance

Cited by 77 publications

References 23 publications

DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer

DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer

CpG Island hypermethylation in cell‐free serum DNA identifies patients with localized prostate cancer

Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities

Contact Info

Product

Resources

About